Scott Mendel - 08 Jul 2025 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Reporting relationship: Director
Issuer ticker: AKYA
Reported as of: 08 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jul 2025, 20:41:09 UTC
Prior SEC filing: 21 May 2025
Next SEC filing: 03 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Scott Mendel

Key filing fact

Scott Mendel filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 10 Jul 2025.

Key facts

This page summarizes Scott Mendel's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
6 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 10 Jul 2025, 20:41.

Change

Previous filing in this sequence was filed on 21 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001515051 Primary reporting owner

Mendel Scott

Relationship: Director
Address: C/O AKOYA BIOSCIENCES, INC., 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH
Signature: /s/ Scott Mendel
Signature date: 10 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKYA transaction

Common Stock

Other

Transaction value
Shares: -28,500
Change %: -100%
Price
Shares after: 0
Date: 08 Jul 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKYA transaction Derivative

Stock Option (right to buy)

Other

Transaction value: $0
Shares: -35,562
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,562
Exercise price: $19.94
Footnotes: F3, F4

AKYA transaction Derivative

Stock Option (right to buy)

Other

Transaction value: $0
Shares: -30,549
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,549
Exercise price: $11.24
Footnotes: F3, F4

AKYA transaction Derivative

Stock Option (right to buy)

Other

Transaction value: $0
Shares: -56,322
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 56,322
Exercise price: $5.70
Footnotes: F3, F4

AKYA transaction Derivative

Stock Option (right to buy)

Other

Transaction value: $0
Shares: -44,959
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 44,959
Exercise price: $2.68
Footnotes: F3, F4

AKYA transaction Derivative

Stock Option (right to buy)

Other

Transaction value: $0
Shares: -50,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $2.01
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Scott Mendel is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.

Footnote F2

In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.

Footnote F3

Disposition of options pursuant to Merger Agreement.

Footnote F4

Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.